24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
IMALIEVA 400MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | IMALIEVA 400MG |
|---|---|
| Composition | Imatinib Mesylate Tablets IP 400mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (3 x 10) |
| Country of Origin | India |
Imatinib Mesylate Tablets IP 400mg (Imatinib Mesylate Tablets IP 400mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
IMALIEVA 400 MG (Imatinib Mesylate Tablets IP 400 mg) is a targeted anticancer medicine used for the treatment of certain blood cancers, gastrointestinal tumors, and other cancers driven by specific genetic abnormalities. It contains Imatinib Mesylate 400 mg, a tyrosine kinase inhibitor (TKI) that works by blocking abnormal proteins responsible for the growth and multiplication of cancer cells.
Imatinib revolutionized cancer treatment by becoming one of the first successful targeted therapies. Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Imatinib specifically targets abnormal enzymes that contribute to cancer progression. This targeted approach helps slow disease progression, improve treatment outcomes, and support long-term cancer management.
IMALIEVA 400 MG is widely prescribed by oncologists and hematologists for patients diagnosed with specific cancers that contain abnormal tyrosine kinase activity. By targeting these cancer-driving proteins, the medicine helps control tumor growth and reduce the spread of disease.
This medicine is commonly used in the treatment of:
• Chronic Myeloid Leukemia (CML)
• Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
• Gastrointestinal Stromal Tumors (GIST)
• Myelodysplastic/Myeloproliferative Disorders (MDS/MPD)
• Hypereosinophilic Syndrome (HES)
• Dermatofibrosarcoma Protuberans (DFSP)
• Advanced Hematological and Solid Tumor Conditions
IMALIEVA 400 MG may be prescribed as a first-line treatment or as part of long-term cancer management programs depending on the patient's diagnosis, treatment history, and response to therapy.
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology care.
Patients receiving Imatinib therapy may require regular blood tests, liver function monitoring, kidney assessments, and periodic medical evaluations to ensure optimal treatment outcomes and early detection of potential side effects.
Due to its proven effectiveness in targeted cancer therapy, IMALIEVA 400 MG has become one of the most important medicines in modern oncology and hematology treatment programs worldwide.
IMALIEVA 400 MG (Imatinib Mesylate Tablets IP 400 mg) is primarily used for the treatment and management of specific cancers and blood disorders.
The medicine is widely used as a standard treatment for chronic myeloid leukemia and helps control abnormal white blood cell growth.
Doctors may prescribe Imatinib for Philadelphia chromosome-positive acute lymphoblastic leukemia.
IMALIEVA helps manage certain gastrointestinal tumors caused by specific genetic mutations.
The medicine may be used in selected blood disorders involving abnormal bone marrow activity.
Imatinib can help manage certain rare blood disorders characterized by excessive eosinophil production.
The medicine supports long-term disease control and targeted oncology treatment programs.
Imatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
IMALIEVA works by:
• Blocking abnormal tyrosine kinase enzymes
• Preventing cancer cell signaling
• Slowing cancer cell growth and multiplication
• Reducing disease progression
• Supporting targeted cancer treatment
• Helping control abnormal blood cell production
This targeted mechanism allows healthcare professionals to manage specific cancers more effectively while preserving healthy tissues.
Like all prescription medicines, IMALIEVA 400 MG may cause side effects in some patients. Side effects vary depending on individual health conditions, treatment duration, and response to therapy.
Patients may experience mild to moderate nausea during treatment.
Some individuals may develop episodes of vomiting.
Weakness, tiredness, or reduced energy levels may occur.
Muscle pain, cramps, or discomfort may develop during therapy.
Digestive disturbances and loose stools may occur.
Fluid retention and swelling around the eyes, hands, feet, or ankles may be observed.
Mild skin irritation, itching, or rash may develop.
Some patients may experience headaches during treatment.
Mild stomach discomfort or abdominal pain may occur.
Seek immediate medical attention if you experience:
• Severe breathing difficulty
• Significant swelling or fluid retention
• Severe liver-related symptoms
• Chest pain
• Severe allergic reactions
• Unusual bleeding or bruising
• Persistent fever
• Severe infection symptoms
• Blood in stool or urine
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of IMALIEVA 400 MG (Imatinib Mesylate Tablets IP 400 mg) should always be determined by a qualified healthcare professional.
Different cancers may require different treatment schedules and dosage plans.
The stage and progression of the disease influence treatment recommendations.
Age, weight, liver function, kidney function, and overall health affect dosage decisions.
Doctors may adjust therapy based on effectiveness and side effect management.
Certain medicines may interact with Imatinib and influence treatment planning.
• Take the tablet exactly as prescribed by your doctor.
• Swallow the tablet whole with water.
• Take the medicine with food if recommended by your healthcare provider.
• Do not crush, chew, or break the tablet unless advised.
• Follow the prescribed treatment schedule carefully.
• Do not discontinue treatment without medical supervision.
Regular follow-up visits and laboratory monitoring are important throughout therapy.
Before starting treatment, patients should inform their doctor if they have:
• Liver disease
• Kidney disease
• Heart disease
• Thyroid disorders
• Blood-related complications
• Previous cancer treatment reactions
Patients should also discuss all prescription medicines, supplements, and herbal products they are currently using to avoid possible drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
• Store in a cool and dry place.
• Protect from direct sunlight and moisture.
• Keep out of reach of children.
• Store at recommended room temperature.
• Trusted Imatinib Mesylate formulation
• Advanced targeted cancer therapy
• Effective treatment for CML and GIST
• Supports long-term disease management
• Manufactured under strict pharmaceutical quality standards
• Suitable for modern oncology and hematology treatment protocols
• Reliable option for targeted cancer care
It is used for the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, acute lymphoblastic leukemia, and certain other blood-related disorders.
Imatinib Mesylate is a targeted anticancer medicine that blocks abnormal tyrosine kinase proteins responsible for cancer growth.
No, it is a targeted therapy medicine known as a tyrosine kinase inhibitor (TKI).
Yes, it helps slow cancer cell growth and supports long-term disease management in eligible patients.
Yes, fluid retention and swelling are among the commonly reported side effects of Imatinib therapy.
Yes, doctors usually recommend blood tests, liver function monitoring, and routine medical evaluations throughout treatment.
No, treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should always be used under the guidance of qualified healthcare professionals experienced in oncology and hematology care.